BioStock: Arcede hopes to reach larger market than existing drugs

Lund-based Arcede Pharma quietly been working away on the drug candidate RCD405 during the second quarter. The second part of the toxicology study is now underway, while the company is continuing preparations for the future beyond preclinical development. BioStock contacted CEO Mia Lundblad to find out more about what is happening in the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/arcede-hopes-to-reach-larger-market-than-existing-drugs/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se